Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.
Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.
Bone marrow fibrosis improvement and variant allele frequency reduction observed with navitoclax plus ruxolitinib for patients with previously treated myelofibrosis may suggest disease modification.
John Mascarenhas, MD, hosts a panel of experts who discusses current strategies used to stratify risk patients with myelofibrosis and their preferences for sequencing therapy.
Ruben Mesa, MD, spoke about why pacritinib in the treatment of myelofibrosis is beneficial.
Ruben Mesa, MD, spoke about which patients stand to benefit the most from the approval of pacritinib in myelofibrosis with severe thrombocytopenia.
Patients with intermediate- or high-risk primary or secondary myelofibrosis with a low platelet count may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.
Ruben Mesa, MD, spoke about the accelerated approval of pacritinib and its importance for the treatment of myelofibrosis with severe thrombocytopenia.
Topline findings from the phase 3 MOMENTUM study indicated that patients with myelofibrosis experienced a statistically significant reduction in symptoms following treatment with momelotinib.
At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about key takeaways learned in the treatment of myelofibrosis during 2021.